Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
News-Medical.Net on MSN
Precision immunotherapy for TRBC2-positive T-cell malignancies
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
News-Medical.Net on MSN
Engineered extracellular vesicles enable antigen-specific regulatory T cell induction
A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has ...
The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...
A new class of engineered extracellular vesicles induces antigen-specific regulatory T cells, offering a targeted strategy ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell ...
A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has ...
Jacobio will get $100 million upfront in the deal and be entitled to an additional $1.92 billion upon meeting certain milestones related to JAB-23E73.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback